Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
1(14%)
Results Posted
33%(2 trials)

Phase Distribution

Ph phase_1
2
29%
Ph phase_2
4
57%
Ph phase_3
1
14%

Phase Distribution

2

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(6)

Detailed Status

Completed6
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 24 (57.1%)
Phase 31 (14.3%)

Trials by Status

recruiting114%
completed686%

Recent Activity

1 active trials
Showing 5 of 7
completedphase_2

Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light

NCT05872854
completedphase_2

Topical SGX302 for Mild-to-Moderate Psoriasis

NCT05442190
recruitingphase_3

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

NCT06470451
completedphase_2

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

NCT06149247
completedphase_2

PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma

NCT05380635
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05872854Phase 2

Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light

Completed
NCT05442190Phase 2

Topical SGX302 for Mild-to-Moderate Psoriasis

Completed
NCT06470451Phase 3

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

Recruiting
NCT06149247Phase 2

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Completed
NCT05380635Phase 2

PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma

Completed
NCT00000792Phase 1

A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects

Completed
NCT00000645Phase 1

A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7